Table 2. Univariate survival analysis of overall survival.
| Clinical factors | P value | Univariate analysis | ||
|---|---|---|---|---|
| HR | 95% CI | |||
| Lower limit | Upper limit | |||
| Gender | 0.02* | 0.538 | 0.316 | 0.9158 |
| Age | 0.27 | 1.016 | 0.988 | 1.045 |
| Operation time | 0.003* | 1.007 | 1.002 | 1.012 |
| Perioperative bleeding | 0.15 | 1.001 | 1.000 | 1.001 |
| BMI | 0.37 | 1.035 | 0.960 | 1.115 |
| Surgical approach | 0.42 | 1.196 | 0.773 | 1.851 |
| ALB | 0.37 | 0.972 | 0.914 | 1.034 |
| CHOL | 0.34 | 0.882 | 0.681 | 1.142 |
| HDL | 0.91 | 0.957 | 0.449 | 2.039 |
| LDL | 0.72 | 0.943 | 0.685 | 1.298 |
| TG | 0.39 | 0.862 | 0.615 | 1.208 |
| MONs | 0.51 | 1.69 | 0.357 | 8.018 |
| MHR | <0.001* | 52.22 | 20.19 | 135.10 |
| Tumor cell type | 0.14 | 1.528 | 0.875 | 2.667 |
| T stage | <0.001* | 1.966 | 1.479 | 2.613 |
| N stage | <0.001* | 2.272 | 1.716 | 3.008 |
| TNM stage | <0.001* | 2.700 | 2.048 | 3.560 |
TNM staging was performed using the American Joint Committee on Cancer TNM staging system, 9th edition. *, P<0.05. ALB, albumin; BMI, body mass index; CHOL, blood cholesterol; CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; MHR, monocyte-to-high-density lipoprotein ratio; MONs, monocytes; N, lymph node; TG, blood triglyceride; T, tumor; TNM, tumor-lymph node-metastasis.